A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...
About The Study: This decision analytic model showed that within the context of a high SARS-CoV-2 probability, monoclonal antibodies pre-exposure prophylaxis (mAbs PrEP) provision was cost-saving when ...
Subdermal delivery of antiretrovirals shows promise in early trials Researchers at the University of California, San Francisco, have found that pre-exposure prophylaxis can be effective in preventing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results